Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PolyPEPI-SCoV-2 vaccine clinical trial for COVID-2019 infections

Trial Profile

A PolyPEPI-SCoV-2 vaccine clinical trial for COVID-2019 infections

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PolyPEPI-SCoV-2 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2020 According to a PepTC Vaccines Limited media release, Pre-IND regulatory confirmations were obtained from FDA (US), MHRA (UK) and PEI (Germany).
    • 22 Jun 2020 New trial record
    • 15 Jun 2020 According to a Treos Bio media release, PepTC Vaccines expects to advance to human clinical studies for its investigational PolyPEPI-SCoV-2 vaccine by October 2020. It expects to have preliminary trial results in March 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top